No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Lincoln Pharmaceuticals Limited, established in 1979 and headquartered in Ahmedabad, India, is a pharmaceutical company engaged in the manufacturing and global distribution of its products. Its comprehensive product line addresses a wide array of medical needs, including dermatological, gynecological, gastrointestinal, and otological conditions. The company also specializes in phosphodiesterase type 5 inhibitors and general anesthetics. Further expanding its therapeutic reach, Lincoln provides treatments for common ailments like coughs, colds, and allergies, alongside anti-asthmatics. Other key product categories include sterile ophthalmic solutions (eye drops and ointments), anti-malarial drugs, and a range of vitamins, minerals, and antioxidants. The portfolio is further diversified with anti-bacterial, anti-viral, and anti-fungal agents; pain relief and fever reduction medications (analgesics and anti-pyretics); and specialized drugs for mental health (anti-psychotics, anti-convulsants, anti-depressants) and diabetes (anti-diabetics). Cardiovascular health is addressed with anti-hypertensives and diuretics, while gastrointestinal issues are targeted with anti-diarrheals, anti-spasmodics, and laxatives. Additionally, the company offers branded generic pharmaceuticals.
www.lincolnpharma.comNo one on the platform currently holds LINCOLN.NS.
No tracked institution reports a position in LINCOLN.NS as of their last filing.
No one on the platform has traded LINCOLN.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.5% | 13.7% | 14.1% | — | — | — |
| Rev. Growth % | 7.7% | 10.1% | ||||
| Profit Margin % | 13.1% | 14.3% | 13.2% | |||
| Free Cash Flow Margin % | 12.1% | 7.9% | 9.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $8.8B | — | $72.00 | $72.00–$72.00 | — | 1 |
| 2028 | $4.0B | -54.5% | $26.87 | $26.87–$26.87 | — | 1 |
| 2029 | $4.0B | -0.2% | $27.35 | $27.35–$27.35 | — | 1 |
| 2030 | $4.2B | +5.2% | $28.22 | $28.22–$28.22 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-20 | $5.20 | $5.81 | +11.7% |
| 2026-02-11 | $6.10 | $14.28 | +134.1% |
| 2025-11-12 | $6.10 | $9.98 | +63.6% |
| 2025-08-07 | $6.10 | $13.82 | +126.6% |
| 2025-05-22 | $5.20 | $5.78 | +11.2% |
| 2025-02-13 | $6.10 | $10.37 | +70.0% |
| 2024-11-14 | $6.10 | $13.15 | +115.6% |
| 2024-08-08 | $6.10 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| LINCOLN.NSLincoln Pharmaceuticals Limited | $600.70 | +1.69% | $12.0B | — |
| INDSWFTLAB.BOInd-Swift Laboratories Limited | $377.80 | +3.68% | $32.8B | — |
| INDSWFTLAB.NSInd-Swift Laboratories Limited | $378.25 | +3.94% | $32.9B | — |
| MAXIND.NSMax India Limited | $140.19 | +0.39% | $7.4B | — |
| SAKAR.NSSakar Healthcare Limited |
| $11.82 |
| +93.8% |
| $1129.55 |
| +2.18% |
| $24.8B |
| — |
| THEMISMED.BOThemis Medicare Limited | $118.45 | -1.62% | $10.9B | — |
| THEMISMED.NSThemis Medicare Limited | $119.85 | +0.08% | $11.0B | — |
Source: Financial Modeling Prep · peers by sector/industry